Common Sensing Secures $6.6M Series A Investment Round to Support Injectable Medicines

Common Sensing , an evidence-based, data-driven injectable-medicine healthcare company, announced the close of a $6.6 million USD Series A financing. The round was led by Waterline Ventures. New World Health, Royal Philips (NYSE: PHG; AEX: PHIA), and Haselmeier joined the round as well. The funds will be used to accelerate Common Sensing's manufacturing and commercial operations for Gocap™, an IP-protected dose monitoring solution enabling patients and providers to better utilize injectable medicine, including insulin, fertility medications, growth hormones, and others.

• Source: 4-traders.
• 614
• April 18, 2018